Abstract 928 AACR 2012 The novel clinical candidate AT13148 is an oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity and a mechanism of action distinct from AKT inhibitors

First Page		Document Content
Oncology Phosphoinositide 3-kinase AKT PTEN HER2/neu Breast cancer Akt/PKB signaling pathway Phosphoinositide-dependent kinase-1 Medicine Biology Protein kinases		Abstract 928 AACR 2012 The novel clinical candidate AT13148 is an oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity and a mechanism of action distinct from AKT inhibitors Add to Reading List Source URL: astx.com Download Document from Source Website File Size: 1,21 MB Share Document on Facebook

	Communications / Middle and Top Management / B1-AKT Intercultural & International Manager Executive Program DocID: 1xVGg - View Document
	ARTS-MONDES-CULTURES and B1-AKT Presents MIGRANTS INTEGRATION LAB Together we build a better DocID: 1xVaM - View Document
	Leadership and Strategy / Global Sustainable Leadership Global Sustainable Leaders B1-AKT Program DocID: 1xV6C - View Document
	Center for Societal Cultural, Entrepreneurship Innovation An international DocID: 1xUWq - View Document
	B1-AKT Strategy Business Innovation Culture Reaching for the Top DocID: 1xUEE - View Document